AXL and ovarian carcinoma: Clinical trials are currently underway to determine the safety and preliminary efficacy of chimeric antigen receptor (CAR)-engineered immune cells, including a phase 1 study of CAR T-cell therapy in patients with advanced AXL-positive lung cancer (NCT03198052) and a phase 1 trial of CAR-NK cells in AXL-positive ovarian cancer and other solid tumors (NCT05410717).